within Pharmacolibrary.Drugs.ATC.P;

model P01BX01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 5e-07,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 1800,            
    Vdp             = 0.031,
    k12             = 0.04,
    k21             = 0.04
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01BX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Halofantrine is an antimalarial agent, classified as a phenanthrene-methanol derivative, used primarily in the past for the treatment of uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax. Due to concerns over its cardiotoxicity (QT prolongation), its clinical use is limited and it is not widely recommended or approved for routine use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Karbwang, J, &amp; Na Bangchang, K (1994). Clinical pharmacokinetics of halofantrine. <i>Clinical pharmacokinetics</i> 27(2) 104–119. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199427020-00003&quot;>10.2165/00003088-199427020-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7955774/&quot;>https://pubmed.ncbi.nlm.nih.gov/7955774</a></p></li><li><p>Dolton, MJ, et al., &amp; Chen, Y (2021). Mechanistic Oral Absorption Modeling of Halofantrine: Exploring the Role of Intestinal Lymphatic Transport. <i>Journal of pharmaceutical sciences</i> 110(3) 1427–1430. DOI:<a href=&quot;https://doi.org/10.1016/j.xphs.2020.12.023&quot;>10.1016/j.xphs.2020.12.023</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33359312/&quot;>https://pubmed.ncbi.nlm.nih.gov/33359312</a></p></li><li><p>Babalola, CP, et al., &amp; Scriba, GK (2009). Effect of fluconazole on the pharmacokinetics of halofantrine in healthy volunteers. <i>Journal of clinical pharmacy and therapeutics</i> 34(6) 677–682. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2710.2009.01064.x&quot;>10.1111/j.1365-2710.2009.01064.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20175801/&quot;>https://pubmed.ncbi.nlm.nih.gov/20175801</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01BX01;
